Drugs in Context is indexed in Clarivate ESCI, is a member of the Directory of Open Access Journals, and is listed on PubMed with all articles free-to-view/download immediately on PubMed Central
Drugs in Context publishes high-quality, peer-reviewed articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. We focus on original research papers and topical review articles; other article types are considered.
Scopus CiteScore 2021: 8.1; SCImago Journal Rank 2021: 1.130; Source Normalized Impact per Paper: 1.915; Ranked 52 of 826 (93rd percentile) in General Medicine journals and 55 of 303 (82nd percentile) in Pharmacology journals.
We publish original research papers and topical review articles. Other article types, including systematic reviews and meta-analyses, editorials, case reports, conference reports and Letters to the Editor, are also considered.
All manuscripts undergo single-blind external peer review with comments from at least two reviewers. A first editorial decision is expected within 4 weeks of submission and online publication within 4 weeks after acceptance.
Check the SUBMISSION page for full instructions. Submit your manuscript via Manuscript Manager.
Drugs in Context is led by a team of Senior Editors supported by an extensive Editorial Board with expertise spanning all areas of modern medicine and pharmacotherapy.
Drugs in Context is an Open Access journal, with articles freely accessible online for all readers. Articles are assessed for suitability upon submission or pre-submission and then sent for external peer review. There is no charge for submitting a manuscript for consideration.
Publication in Drugs in Context is facilitated by our dedicated and responsive Editorial team. We offer simple and straightforward publication following best practices. For detailed submission guidelines, how to prepare your manuscript, timelines and charges, please read this section.
This comprehensive review aims to provide readers with the current data on the use of aspirin as a primary prevention tool for atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels.
